泡泡玛特:IP持续出圈印证运营能力,回购体现公司信心-20260123
Guosen International· 2026-01-23 07:45
Investment Rating - The report does not specify a clear investment rating for the company [6] Core Insights - The company has demonstrated strong operational capabilities in IP management, with recent product innovations leading to increased sales potential for Q1 [1][2] - Recent stock buybacks, totaling over 300 million HKD, reflect the company's confidence in its long-term growth prospects and indicate that the stock price is at a relatively low level [1][3] - The company has successfully launched new product lines that have gained significant market traction, suggesting a robust ability to diversify its IP portfolio [2] Summary by Sections Product Performance - The Pucky Knock Knock series blind boxes have gained popularity, showcasing the company's innovative approach to IP [2] - The company has also launched successful series for the New Year and Valentine's Day, indicating strong consumer demand [2] Stock Buyback Activity - The company repurchased 1.4 million shares at an average price of 161 HKD and 500,000 shares at 173 HKD, demonstrating confidence in its stock valuation [3] - The stock buybacks are seen as a strategic move to bolster market confidence and counteract short-selling pressures [3] Market Outlook - The company has a strong presence in overseas markets, with approximately 200 stores globally, and continues to expand its footprint [4] - Future revenue projections indicate significant growth, with expected revenues of 373.98 billion RMB in 2025, reflecting a year-over-year growth of 186.8% [12] - The company's P/E ratios for 2025, 2026, and 2027 are projected to be 20.70, 15.25, and 12.26 respectively, suggesting that the current valuation is relatively low for a high-growth company [4][12]
映恩生物-B(9606.HK)事件点评:引领ADC迭代浪潮,2026年有望实现商业化
Guolian Minsheng Securities· 2026-01-23 07:25
映恩生物-B(9606.HK)事件点评 引领 ADC 迭代浪潮,2026 年有望实现商业化 glmszqdatemark 2026 年 01 月 23 日 事件:2026 年 1 月 19 日,映恩生物宣布,自主研发的 ADAM9 ADC 药物 DB- 1317 已正式获得 NMPA 药品审评中心(CDE)的 IND 批准,同意其单药在晚 期/转移性恶性实体瘤患者中开展临床试验。 | 分析师 | 张金洋 | | --- | --- | | 执业证书: S0590525120012 | | | 邮箱: | zhangjinyang@glms.com.cn | | 分析师 | 胡偌碧 | | 执业证书: S0590525120011 | | | 邮箱: | huruobi@glms.com.cn | | 分析师 | 郭广洋 | | 执业证书: S0590525120010 | | | 邮箱: | guoguangyang@glms.com.cn | 相对走势 -10% 53% 117% 180% 2025/4 2025/9 2026/1 映恩生物-B 恒生指数 本公司具备证券投资咨询业务资格,请务必阅读最后一页免 ...
泡泡玛特(09992):IP持续出圈印证运营能力,回购体现公司信心
国投证券(香港)· 2026-01-23 07:07
SDICSI 2026 年 1 月 23 日 泡泡玛特(9992.HK) IP 持续出圈印证运营能力,回购体现公司信心 事件:近期,公司在品类上做了更多的创新尝试,PUCKY 敲敲系列盲盒的出 圈、星星人怦然星动系列销售火热、以及新年马力全开系列毛绒受热捧,都印 证了公司对 IP 的运营能力,预计给 Q1 的销售带来更多增量。此外,公司近 日连续进行回购,1 月 19 日和 1 月 21 日共斥资超 3 亿港元进行回购,这也 彰显了公司对于中长期发展的信心。此前股价已从顶部下跌近 4 成,近期估值 开始修复,但仍处于合理偏低水平,推荐持续关注。 报告摘要 新品持续热销,有望给 Q1 的销售带来更多增量。近期,泡泡玛特 Pucky 敲敲 系列盲盒出圈,该产品是泡泡玛特旗下 IP 之一 Pucky 毕奇的最新系列"Pucky 敲敲系列搪胶毛绒挂件",售价 99 元/盒,有"机敏"、"快乐"、"缘分"、"幸 运"、"智慧"、"财富"和隐藏款"成功"。产品特性是带有声音互动功能,通过 拍打毕奇脑袋,可以发出清脆的类似敲击木鱼的声音,符合当下打工人热爱玄 学的精神状态。该系列也因其敲击玩法被称为"电子木鱼"而出圈,和此 ...
中国船舶租赁(03877):通过可转债实现低利率融资,特别分红重视股东回报:中国船舶租赁(03877):
Shenwan Hongyuan Securities· 2026-01-23 05:34
曲公司 非領令融 2026 年 01 月 23 日 中国船舶積領 通过可转债实现低利率融资,特别分红重视股东回报 报告原因:有信息公布需要点评 (维持) | 市场数据: | 2026 年 01 月 22 日 | | --- | --- | | 收盘价(港币) | 2.14 | | 恒生中国企业指数 | 9114.3 | | 52 周最高/最低(港币) | 2.40/1.55 | | H 股市值(亿港币) | 132.66 | | 流通 H 股(百万股) | 6,199.22 | | 汇率(港币/人民币) | 0.8982 | 一年内股价与基准指数对比走势: 51% 31% 资料来源:Bloomberg 相关研究 证券分析师 王晨鉴 A0230525030001 wangcj@swsresearch.com 闫海 A0230519010004 yanhai@swsresearch.com 联系人 王晨鉴 A0230525030001 wangcj@swsresearch.com 申万宏源研究微信服务号 投资要点: 财务数据及盈利预测 | 港元 | 2023 | 2024 | 2025E | 2026E | 20 ...
映恩生物-B(09606):引领ADC迭代浪潮,2026年有望实现商业化
Guolian Minsheng Securities· 2026-01-23 05:24
| 单位/百万人民币 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入(百万元) | 1,941 | 1,950 | 1,972 | 2,100 | | 增长率(%) | 8.7 | 0.5 | 1.1 | 6.5 | | 归属母公司股东净利润(百万元) | -1,050 | -247 | -386 | -341 | | 增长率(%) | -193.8 | 76.5 | -56.1 | 11.5 | | 每股收益(元) | -11.75 | -2.76 | -4.31 | -3.82 | | PE(X) | / | / | / | / | | PS(X) | / | 14 | 14 | 13 | 资料来源:Wind,国联民生证券研究所预测(注:股价为 2026 年 01 月 21 日收盘价,汇率 1HKD=0.89RMB) 2026 年 01 月 23 日 事件:2026 年 1 月 19 日,映恩生物宣布,自主研发的 ADAM9 ADC 药物 DB- 1317 已正式获得 NMPA 药品审评中心(CDE)的 IN ...
中国船舶租赁(03877):通过可转债实现低利率融资,特别分红重视股东回报
Shenwan Hongyuan Securities· 2026-01-23 03:43
上 市 公 司 非银金融 2026 年 01 月 23 日 中国船舶租赁 (03877) ——通过可转债实现低利率融资,特别分红重视股东回报 报告原因:有信息公布需要点评 买入(维持) | 市场数据: | 2026 年 01 月 22 日 | | --- | --- | | 收盘价(港币) | 2.14 | | 恒生中国企业指数 | 9114.3 | | 52 周最高/最低(港币) | 2.40/1.55 | | H 股市值(亿港币) | 132.66 | | 流通 H 股(百万股) | 6,199.22 | | 汇率(港币/人民币) | 0.8982 | 一年内股价与基准指数对比走势: -9% 11% 31% 51% HSCEI 中国船舶租赁 资料来源:Bloomberg 相关研究 - 证券分析师 投资要点: 财务数据及盈利预测 | 港元 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 3,745 | 4,441 | 4,286 | 4,541 | 4,821 | | 同 ...
TCL电子:联手索尼,迎来全球化高端化发展里程碑-20260123
First Shanghai Securities· 2026-01-23 02:20
Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 15.00, representing a potential upside of 37.7% from the current price of HKD 10.89 [6]. Core Insights - The company is expected to achieve a net profit of HKD 2.53 billion to HKD 2.57 billion in 2025, reflecting a growth of 45% to 60% compared to 2024, which aligns with the company's equity incentive targets [8]. - The TV segment has shown significant improvement, with a 5.3% increase in TV shipments to 21.08 million units in the first three quarters of 2025, and a remarkable 153% growth in global shipments of TCL MiniLED TVs [8]. - A joint venture with Sony is set to enhance global and high-end development, with TCL holding a 51% stake. This partnership is expected to leverage TCL's supply chain and cost control advantages alongside Sony's advanced imaging technology and brand value [8]. - The report anticipates that the collaboration will allow TCL to transition from "scale expansion" to "brand globalization," enhancing its market share in high-end segments [8]. Financial Summary - Revenue is projected to grow from HKD 78.99 billion in 2023 to HKD 153.96 billion by 2027, with a compound annual growth rate (CAGR) of 13.5% [4]. - The gross profit margin is expected to stabilize around 15.7% by 2027, with net profit increasing from HKD 744 million in 2023 to HKD 3.51 billion in 2027 [4][9]. - Earnings per share (EPS) is forecasted to rise from HKD 0.33 in 2023 to HKD 1.39 in 2027, indicating a strong growth trajectory [4][9]. - The company’s price-to-earnings (P/E) ratio is projected to decrease from 32.9x in 2023 to 7.8x by 2027, suggesting an attractive valuation as earnings grow [4].
泡泡玛特:回购彰显成长信心,产品持续出奇创新-20260123
HTSC· 2026-01-23 02:15
港股通 回购彰显成长信心,产品持续出奇创新 证券研究报告 泡泡玛特 (9992 HK) | 华泰研究 | | | 动态点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | --- | | 2026 年 | 1 月 | 22 日│中国香港 | 消费轻工 | 目标价(港币): | 410.00 | 公司近日开启股份回购,1 月 19 日、21 日两次回购合计 190 万股,回购金 额 3.1 亿港元。公司曾于 4M23-2M24 持续回购,累计约 2465 万股,金额 约 4.6 亿港元,平均单笔 36 万股。本轮回购的单笔金额及股数均超过以往, 彰显公司对成长前景信心。公司在门店运营精细度、场景氛围、情感体验等 方面不断精进,已长期论证的 IP 创新、品类创新能力持续发力,不断带动 新 IP、新玩法出圈。我们看好公司在 26 年加快 IP 结构多元化、均衡化, 乐园、动画内容、甜品、饰品等业态加快落地,培育新增长点并强化 IP 情 感连接,缓解市场对时尚风险的担忧。维持"买入"评级,继续重点推荐。 新品玩法、创意不断出新,持续验证 IP 运营能力 近期公司多 ...
周大福:主要经营数据点评同店销售提速,内地定价首饰高增-20260123
GUOTAI HAITONG SECURITIES· 2026-01-23 00:25
周大福 FY2026Q3 主要经营数据点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | [Table_Invest] 评级: | 增持 | | --- | --- | --- | --- | --- | --- | | 刘越男(分析师) | 021-38677706 | liuyuenan@gtht.com | S0880516030003 | | | | 宋小寒(分析师) | 010-83939087 | songxiaohan@gtht.com | S0880524080011 | [当前价格 Table_CurPrice] (港元): | 14.12 | 本报告导读: 中国内地高毛利率定价产品占比提升。 同店销售提速,内地定价首饰高增 周大福(1929) [Table_Market] 交易数据 | 52 周内股价区间(港元) | 6.76-16.63 | | --- | --- | | 当前股本(百万股) | 9,865 | | 当前市值(百万港元) | 139,299 | [Table_PicQuote] 52周股价走势图 0% 30% 61% 91% 121% 15 ...
百度集团-SW:4Q经营现金流持续为正,昆仑芯上市有望持续释放估值-20260123
海通国际· 2026-01-23 00:24
研究报告 Research Report 22 Jan 2026 百度集团-SW Baidu (9888 HK) 4Q 经营现金流持续为正,昆仑芯上市有望持续释放估值 Able to maintain positive OCF in Q4, KLX's listing unlocks valuation [Table_yemei1] 观点聚焦 Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$160.00 目标价 HK$178.00 HTI ESG 5.0-5.0-5.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$440.00bn / US$62.84bn 日交易额 (3 个月均值) US$229.01mn 发行股票数目 2,226mn 自由流通股 (%) 96% 1 年股价最高最低值 HK$160.00-HK$75.50 注:现价 HK$160.00 为 2026 年 01 月 22 日收盘价 资料来源: ...